Most hyperpigmentation has a recognisable pattern. Brown marks at the site of a breakout. Symmetrical patches driven by hormones. Scattered spots from cumulative sun exposure. The colour, location, and behaviour point toward a type, and from there toward an approach.
Medication-related pigmentation does not always follow those patterns. The colour can be blue-grey, slate, or muddy brown rather than the warm browns of PIH or melasma. The distribution can be unusual: the shins, the hard palate, the nails, areas that other types of hyperpigmentation do not typically affect. And the behaviour is tied not to sun exposure or hormones but to the accumulation of a drug or its metabolites in the skin.
Recognising this pattern matters because the response is fundamentally different from every other type in the guide. The first step is not a topical or a procedure. It is a conversation with the prescriber about the medication involved.
How medication-related pigmentation differs
Three features distinguish drug-induced pigmentation from other types:
Unusual colour. While most hyperpigmentation presents as shades of brown, medication-related pigment frequently has a blue-grey, slate-blue, grey-brown, or even yellowish cast. This reflects the fact that the pigment is often not melanin alone. Some drugs or their metabolites deposit directly in the skin, producing colours that melanin does not.
Unusual distribution. Drug-induced pigmentation can appear in locations that other types rarely affect: the shins, the oral mucosa, the nail beds, the sclera (whites of the eyes), and sun-exposed areas in patterns that do not match melasma or PIH. When pigment appears somewhere unexpected, medication should be on the list of potential causes.
Temporal correlation with a drug. The pigmentation appeared or worsened after starting, increasing, or changing a medication. This is the most important diagnostic clue. If the timing aligns, the association is worth investigating even if the colour and distribution look unusual.
Medications most commonly involved
| Medication class | Common examples | Typical pigment pattern | Common locations |
|---|---|---|---|
| Tetracyclines | Minocycline (most common), doxycycline | Blue-grey to slate-blue; can also appear brown or muddy | Shins, forearms, acne scars, oral mucosa, teeth, nails |
| Antimalarials | Hydroxychloroquine, chloroquine | Blue-grey to brown-grey | Shins, face, hard palate, nails |
| Chemotherapy agents | Cyclophosphamide, doxorubicin, 5-FU, bleomycin | Diffuse darkening or patterned (flagellate with bleomycin) | Nails, skin folds, mucous membranes, palms, diffuse |
| Psychiatric medications | Chlorpromazine, other phenothiazines | Slate-grey to blue-grey; may affect exposed areas | Sun-exposed skin, especially face |
| Cardiac medications | Amiodarone | Blue-grey (photodistributed) | Sun-exposed areas: face, hands, forearms |
| Heavy metals (therapeutic) | Gold (chrysotherapy), silver (argyria) | Blue-grey (silver) or blue-black (gold) | Diffuse, especially sun-exposed areas |
| NSAIDs | High-dose or chronic use | Brown patches, usually mild | Variable |
| Oral contraceptives | Combined oestrogen-progestin | Melasma pattern (this is hormonal pigmentation, not direct drug deposition) | Face: cheeks, forehead, upper lip |
A note on oral contraceptives: The pigmentation associated with hormonal contraceptives is typically melasma, driven by the hormonal signalling effect of oestrogen and progestin on melanocytes. This is mechanistically different from direct drug deposition (as with minocycline or amiodarone). It is included in this table because the medication is the trigger, but the type and management approach align with melasma rather than drug-induced pigmentation. The melasma and the birth control articles cover this in full.
The mechanism varies by drug
Not all medication-related pigmentation works the same way. The mechanism depends on the specific drug.
Direct deposition. Some drugs or their metabolites accumulate in the skin and deposit as visible pigment. Minocycline is the classic example: it forms insoluble complexes with melanin, iron, and calcium that deposit in the dermis, producing the characteristic blue-grey colour. Silver (argyria) is another direct deposition process.
Melanin stimulation. Some drugs stimulate melanocytes to produce excess melanin, producing pigmentation that looks more like conventional hyperpigmentation (brown, in typical locations). Oral contraceptives work through this mechanism via hormonal signalling.
Photosensitisation. Some drugs increase the skin's sensitivity to UV, causing an exaggerated pigment response to normal sun exposure. The pigmentation appears in sun-exposed areas and may look like an accelerated version of sun damage. Amiodarone and chlorpromazine can produce this pattern.
Drug-melanin complex formation. Some drugs bind to melanin already present in the skin, changing its colour or making it more visible. This is part of the minocycline mechanism and also contributes to the pigmentation seen with antimalarials.
Understanding the mechanism is not essential for the person experiencing it, but it helps explain why the colour and distribution look so different from typical hyperpigmentation, and why the primary response is addressing the medication rather than the pigment.
How it behaves over time
The timeline for medication-related pigmentation varies depending on the drug, the mechanism, and how long the medication has been used.
Drug-stimulated melanin (as with oral contraceptives) may begin to fade once the medication is stopped, though the timeline follows melasma patterns: gradual, often incomplete, and susceptible to reactivation by other triggers.
Direct drug deposition (as with minocycline or heavy metals) can be much more persistent. The deposited material is not melanin and is not cleared by the same mechanisms. Minocycline pigmentation can take months to years to fade after discontinuation, and some deposits may be permanent without laser intervention.
Photosensitisation-related pigment may fade relatively well once the drug is stopped and sun protection is maintained, because the underlying mechanism (exaggerated UV response) ceases.
In general, the earlier the association is identified and addressed, the better the outcome. Pigmentation that has been accumulating for months or years of continued medication use is harder to resolve than pigmentation caught early.
What to ask your prescriber
If you suspect a medication is causing pigment changes, the conversation with your prescriber is the most important step. Nothing here is a recommendation to stop or change any medication. That decision involves weighing the pigmentation concern against the medical reason the drug was prescribed, and that calculus is your prescriber's domain.
Questions worth raising:
- Is pigmentation a known side effect of this specific medication at my dose?
- Is there an alternative medication that carries a lower pigmentation risk while being equally effective for my condition?
- If I continue the medication, is the pigmentation likely to stabilise or continue progressing?
- If I stop or switch, what is the expected timeline for the pigmentation to improve?
- Would any supportive measures (enhanced sun protection, specific topical treatments) help while I remain on the medication?
These are reasonable questions. Prescribers may not always raise pigmentation proactively because it is a cosmetic side effect in the context of medications prescribed for serious conditions. But most will engage with the conversation if you raise it.
When to see a dermatologist
If pigmentation appeared after starting a medication and you want confirmation of the association. A dermatologist can assess the pattern, colour, and distribution to determine whether the presentation is consistent with drug-induced pigmentation or whether something else is contributing.
If the pigmentation has a blue-grey or slate colour in unusual locations. This presentation is distinctive enough that a dermatologist can usually narrow the differential quickly, and a skin biopsy can confirm drug deposition if needed.
If the pigmentation is affecting your quality of life and you want to explore treatment options. Some drug-induced pigmentation responds to specific laser treatments (particularly Q-switched lasers for minocycline deposits). A dermatologist can assess whether treatment is feasible for your specific presentation.
If you are unsure whether the pigmentation is medication-related or another type. Drug-induced pigmentation in sun-exposed facial areas can overlap visually with melasma. If the timing correlates with a medication, both may be relevant.
Medication-related pigmentation often looks different from every other type in the guide. If the colour is unusual, the location is unexpected, or the timing matches a prescription, the medication is worth investigating before the skincare routine.
